```
=> d his

     (FILE 'HOME' ENTERED AT 03:20:47 ON 13 JUN 2007)

     FILE 'CAPLUS' ENTERED AT 03:20:56 ON 13 JUN 2007
L1             1 S US2005-559857/APPS

     FILE 'REGISTRY' ENTERED AT 03:21:13 ON 13 JUN 2007

     FILE 'CAPLUS' ENTERED AT 03:21:15 ON 13 JUN 2007
L2             TRA L1 1- RN :       78 TERMS

     FILE 'REGISTRY' ENTERED AT 03:21:15 ON 13 JUN 2007
L3           78 SEA L2

     FILE 'REGISTRY' ENTERED AT 03:59:21 ON 13 JUN 2007
L4             STRUCTURE UPLOADED
L5             4 S L4

     FILE 'STNGUIDE' ENTERED AT 04:00:06 ON 13 JUN 2007

     FILE 'REGISTRY' ENTERED AT 04:00:48 ON 13 JUN 2007
L6       1668613 S NC4/ES
L7             0 S L4 SAM SUB=L6
L8          1899 S L4 SSS FULL SUB=L6
               SAV TEM L8 BRD559857/A

     FILE 'CAPLUS' ENTERED AT 04:02:34 ON 13 JUN 2007
L9            67 S L8

     FILE 'STNGUIDE' ENTERED AT 04:03:04 ON 13 JUN 2007

     FILE 'CAPLUS' ENTERED AT 04:03:24 ON 13 JUN 2007

=> d l4
L4 HAS NO ANSWERS
L4             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
```

```
=> d his

     (FILE 'HOME' ENTERED AT 06:33:55 ON 13 JUN 2007)

     FILE 'CAPLUS' ENTERED AT 06:34:06 ON 13 JUN 2007
L1             1 S US2005-559857/APPS

     FILE 'STNGUIDE' ENTERED AT 06:35:08 ON 13 JUN 2007

     FILE 'CAPLUS' ENTERED AT 06:38:27 ON 13 JUN 2007

     FILE 'REGISTRY' ENTERED AT 06:38:40 ON 13 JUN 2007
                ACT BRD559857/A
                ---------
L2                STR
L3   (   1668613)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC4/ES
L4          1899 SEA FILE=REGISTRY SUB=L3 SSS FUL L2
                ---------

     FILE 'CAPLUS' ENTERED AT 06:38:51 ON 13 JUN 2007
L5            67 S L4
L6             1 S L1 AND L5

     FILE 'REGISTRY' ENTERED AT 06:44:39 ON 13 JUN 2007
L7                STRUCTURE UPLOADED
L8             0 S L7 SAM SUB=L4

     FILE 'STNGUIDE' ENTERED AT 06:45:25 ON 13 JUN 2007

     FILE 'REGISTRY' ENTERED AT 06:46:47 ON 13 JUN 2007
L9                STRUCTURE UPLOADED
L10            1 S L9 SAM SUB=L4
L11           11 S L9 SSS FULL SUB=L4

     FILE 'CAPLUS' ENTERED AT 06:47:39 ON 13 JUN 2007
L12            2 S L11

=> d l9
L9 HAS NO ANSWERS
L9                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> d his

     (FILE 'HOME' ENTERED AT 06:33:55 ON 13 JUN 2007)

     FILE 'CAPLUS' ENTERED AT 06:34:06 ON 13 JUN 2007
L1             1 S US2005-559857/APPS

     FILE 'STNGUIDE' ENTERED AT 06:35:08 ON 13 JUN 2007

     FILE 'CAPLUS' ENTERED AT 06:38:27 ON 13 JUN 2007

     FILE 'REGISTRY' ENTERED AT 06:38:40 ON 13 JUN 2007
                ACT BRD559857/A
                ---------
L2              STR
L3   (   1668613)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC4/ES
L4          1899 SEA FILE=REGISTRY SUB=L3 SSS FUL L2
                ---------

     FILE 'CAPLUS' ENTERED AT 06:38:51 ON 13 JUN 2007
L5            67 S L4
L6             1 S L1 AND L5

     FILE 'REGISTRY' ENTERED AT 06:44:39 ON 13 JUN 2007
L7              STRUCTURE UPLOADED
L8             0 S L7 SAM SUB=L4

     FILE 'STNGUIDE' ENTERED AT 06:45:25 ON 13 JUN 2007

     FILE 'REGISTRY' ENTERED AT 06:46:47 ON 13 JUN 2007
L9              STRUCTURE UPLOADED
L10            1 S L9 SAM SUB=L4
L11           11 S L9 SSS FULL SUB=L4

     FILE 'CAPLUS' ENTERED AT 06:47:39 ON 13 JUN 2007
L12            2 S L11
L13            0 S L5 AND KIM/IN
L14           17 S L5 AND KSP

=>
```

C:\Program Files\Stnexp\Queries\10559857-brd.str





chain nodes :
1 2 11 12 15 17 21
ring nodes :
5 6 7 8 9
ring/chain nodes :
16
chain bonds :
1-9 2-7 5-11 11-12 12-15 12-21
ring bonds :
5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
1-9 2-7 5-6 5-9 5-11 6-7 7-8 8-9 11-12 12-15 12-21
isolated ring systems :
containing 5 :

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS 12:CLASS
15:CLASS 16:CLASS 17:CLASS 21:CLASS
Generic attributes :
1:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
2:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
17:
Saturation : Saturated

Element Count :

Node 1: Limited
C,C6

Node 2: Limited
C,C6

=> d l12 tot bib abs hitstr

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:188863 CAPLUS
DN 144:432640
TI Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility
AU Garbaccio, Robert M.; Fraley, Mark E.; Tasber, Edward S.; Olson, Christy M.; Hoffman, William F.; Arrington, Kenneth L.; Torrent, Maricel; Buser, Carolyn A.; Walsh, Eileen S.; Hamilton, Kelly; Schaber, Michael D.; Fernandes, Christine; Lobell, Robert B.; Tao, Weikang; South, Vicki J.; Yan, Youwei; Kuo, Lawrence C.; Prueksaritanont, Thomayant; Slaughter, Donald E.; Shu, Cathy; Heimbrook, David C.; Kohl, Nancy E.; Huber, Hans E.; Hartman, George D.
CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(7), 1780-1783
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:432640
AB 2,4-Diaryl-2,5-dihydropyrroles have been discovered to be novel, potent and water-soluble inhibitors of KSP, an emerging therapeutic target for the treatment of cancer. A potential concern for these basic KSP inhibitors was hERG binding that can be minimized by incorporation of a potency-enhancing C-2 phenol combined with neutral N-1 side chains. Aqueous solubility was restored to these, and other, non-basic inhibitors, through a phosphate prodrug strategy.
IT 812667-21-3P 812667-26-8P 884651-23-4P
884651-24-5P 884651-25-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2,4-diaryl-2,5-dihydropyrroles as kinesin spindle protein (KSP) inhibitors with reduced hERG binding and phosphate prodrugs for aqueous solubility)
RN 812667-21-3 CAPLUS
CN Phosphoric acid, 3-[(2S)-4-(2,5-difluorophenyl)-1-[(dimethylamino)carbonyl]-2,5-dihydro-1H-pyrrol-2-yl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-26-8 CAPLUS
CN Carbamic acid, [(1S)-1-[[(2S)-4-(2,5-difluorophenyl)-2,5-dihydro-2-phenyl-1H-pyrrol-1-yl]carbonyl]-2,2-dimethylpropyl]-, 2-[[bis(phenylmethoxy)phosphinyl]oxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 884651-23-4 CAPLUS
CN Phosphoric acid, 3-[(2S)-1-[(2S)-cyclopropylhydroxyacetyl]-4-(2,5-difluorophenyl)-2,5-dihydro-1H-pyrrol-2-yl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 884651-24-5 CAPLUS
CN Phosphoric acid, 3-[(2S)-4-(2,5-difluorophenyl)-2,5-dihydro-1-[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]-1H-pyrrol-2-yl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 884651-25-6 CAPLUS

CN Phosphoric acid, (1S)-1-cyclopropyl-2-[(2S)-4-(2,5-difluorophenyl)-2,5-dihydro-2-phenyl-1H-pyrrol-1-yl]-2-oxoethyl dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 812667-22-4P 812667-23-5P 812667-25-7P
812667-27-9P 812667-28-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2,4-diaryl-2,5-dihydropyrroles as kinesin spindle protein (KSP) inhibitors with reduced hERG binding and phosphate prodrugs for aqueous solubility)

RN 812667-22-4 CAPLUS

CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-N,N-dimethyl-2-[3-(phosphonooxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-23-5 CAPLUS

CN 1H-Pyrrole, 1-[(2S)-cyclopropylhydroxyacetyl]-4-(2,5-difluorophenyl)-2,5-dihydro-2-[3-(phosphonooxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-25-7 CAPLUS
CN 1H-Pyrrole, 4-(2,5-difluorophenyl)-2,5-dihydro-1-[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]-2-[3-(phosphonooxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-27-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[(2S)-4-(2,5-difluorophenyl)-2,5-dihydro-2-phenyl-1H-pyrrol-1-yl]carbonyl]-2,2-dimethylpropyl]-, 2-(phosphonooxy)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-28-0 CAPLUS
CN 1H-Pyrrole, 1-[(2S)-cyclopropyl(phosphonooxy)acetyl]-4-(2,5-

difluorophenyl)-2,5-dihydro-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1127483 CAPLUS
DN 142:74446
TI A preparation of pyrrole derivatives, useful as mitotic kinesin inhibitors
IN Fraley, Mark E.; Garbaccio, Robert M.; Hartman, George D.; Hoffman, William F.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004111193	A2	20041223	WO 2004-US18065	20040608
	WO 2004111193	A3	20050324		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004248160	A1	20041223	AU 2004-248160	20040608
	CA 2527582	A1	20041223	CA 2004-2527582	20040608
	EP 1636182	A2	20060322	EP 2004-754621	20040608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1805928	A	20060719	CN 2004-80016354	20040608
	JP 2007505949	T	20070315	JP 2006-533588	20040608
	US 2006135594	A1	20060622	US 2005-559857	20051207
PRAI	US 2003-477995P	P	20030612		
	WO 2004-US18065	W	20040608		

OS MARPAT 142:74446
GI



I



II



III

AB The invention relates to a preparation of pyrrole derivs. of formula I [wherein: R1 is (alkylene)0-1C(O)-alk(en/yn)yl, (alkylene)0-1C(S)-alk(en/yn)yl, or (alkylene)0-1-SO2-alkyl, etc.; R2 and R6 are independently selected from aryl, cycloalkyl, heterocyclyl, or aralkyl; R3, R4, R5, R7, R8, and R9 are independently selected from H, alk(en/yn)yl, aryl, or heterocyclyl, etc.], useful as mitotic kinesin inhibitors (no biol. data). The invention compds. are useful for the treatment of proliferative diseases such as cancer, hyperplasia, restenosis, and immune disorders. For instance, pyrrolecarboxamide derivative II was prepared via phenylation of N-BOC-pyrrol derivative III by PhN2+•BF4-, N-deprotection, and N-carboxamidation by ClC(O)NMe2 (scheme 1).

IT 812667-22-4P 812667-23-5P 812667-24-6P
812667-25-7P 812667-27-9P 812667-28-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrole derivs. useful as mitotic kinesin inhibitors)

RN 812667-22-4 CAPLUS

CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-N,N-dimethyl-2-[3-(phosphonooxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-23-5 CAPLUS

CN 1H-Pyrrole, 1-[(2S)-cyclopropylhydroxyacetyl]-4-(2,5-difluorophenyl)-2,5-

dihydro-2-[3-(phosphonooxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-24-6 CAPLUS
CN 1H-Pyrrole-1-carboxamide, 4-(2,5-difluorophenyl)-2,5-dihydro-N-methyl-2-[3-(phosphonooxy)phenyl]-N-(tetrahydro-3-furanyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-25-7 CAPLUS
CN 1H-Pyrrole, 4-(2,5-difluorophenyl)-2,5-dihydro-1-[(2S)-2-hydroxy-3,3-dimethyl-1-oxobutyl]-2-[3-(phosphonooxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-27-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[(2S)-4-(2,5-difluorophenyl)-2,5-dihydro-2-phenyl-1H-pyrrol-1-yl]carbonyl]-2,2-dimethylpropyl]-, 2-(phosphonooxy)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-28-0 CAPLUS
CN 1H-Pyrrole, 1-[(2S)-cyclopropyl(phosphonooxy)acetyl]-4-(2,5-difluorophenyl)-2,5-dihydro-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 812667-21-3P 812667-26-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrole derivs. useful as mitotic kinesin inhibitors)
RN 812667-21-3 CAPLUS
CN Phosphoric acid, 3-[(2S)-4-(2,5-difluorophenyl)-1-[(dimethylamino)carbonyl]-2,5-dihydro-1H-pyrrol-2-yl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812667-26-8 CAPLUS
CN Carbamic acid, [(1S)-1-[[(2S)-4-(2,5-difluorophenyl)-2,5-dihydro-2-phenyl-1H-pyrrol-1-yl]carbonyl]-2,2-dimethylpropyl]-, 2-[[bis(phenylmethoxy)phosphinyl]oxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.01	69.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-3.12

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:48:26 ON 13 JUN 2007

=> d l14 17 bib abs

L14 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:1006780 CAPLUS
DN 140:77020
TI Preparation of pyrrole derivatives as mitotic kinesin inhibitors
IN Arrington, Kenneth L.; Coleman, Paul J.; Cox, Christopher D.; Fraley, Mark E.; Garbaccio, Robert M.; Hartman, George D.; Hoffman, William F.; Tasber, Edward S.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 401 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003105855	A1	20031224	WO 2003-US18482	20030612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487489	A1	20031224	CA 2003-2487489	20030612
	AU 2003245453	A1	20031231	AU 2003-245453	20030612
	BR 2003011784	A	20050308	BR 2003-11784	20030612
	EP 1515724	A1	20050323	EP 2003-739093	20030612
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1674906	A	20050928	CN 2003-819318	20030612
	JP 2005536479	T	20051202	JP 2004-512758	20030612
	ZA 2004009334	A	20060222	ZA 2004-9334	20041119
	US 2006105997	A1	20060518	US 2004-517559	20041208
	IN 2004CN02798	A	20060210	IN 2004-CN2798	20041210
	NO 2005000198	A	20050311	NO 2005-198	20050113
PRAI	US 2002-388621P	P	20020614		
	US 2002-403830P	P	20020815		
	US 2002-426940P	P	20021115		
	US 2003-458318P	P	20030328		
	WO 2003-US18482	W	20030612		

OS MARPAT 140:77020
GI



I



II

AB The invention relates to dihydropyrrole compds. that are useful for treating cellular proliferative diseases and disorders associated with

KSP kinesin activity. The invention also relates to compns. which comprise these compds. and methods of using them to treat cancer in mammals. Compds. I [R1 is (C1-C6-alkylene)n-X-R, (n is 0 or 1; X is CO, SO2, NH, PO, etc.; R is alkyl, aryl, amino group, etc.), aryl, heterocyclyl, or alkyl; R2, R6 are aryl, aralkyl, cycloalkyl, or heterocyclyl; R3-R5, R7-R9 are H, alk(en)(yn)yl, aryl, aralkyl, heterocyclyl, etc.] (including amino acid derivs.) are claimed. For example, a detailed synthesis for the preparation of II is outlined, which includes reaction of 2 chloro-5-fluorobenzenediazonium tetrafluoroborate with Boc-protected 2,5-dihydro-1H-pyrrole-1-carboxylate.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr

L14 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
IT 639074-56-9 639074-88-7 639074-89-8
639074-95-6 639075-61-9 639078-11-8
812667-20-2 884902-56-1 884902-57-2
884902-58-3
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacophore of KSP inhibitors)
RN 639074-56-9 CAPLUS
CN 1H-Pyrrole, 1-[(2S)-aminocyclopropylacetyl]-4-(2,5-difluorophenyl)-2,5-dihydro-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639074-88-7 CAPLUS
CN 1H-Pyrrole, 1-[(2S)-2-amino-3-methyl-1-oxobutyl]-4-(2,5-difluorophenyl)-2,5-dihydro-2-(3-hydroxyphenyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.